Research progress on factors influencing the therapeutic effect of gemtuzumab ozo-gamicin for acute myeloid leukemia / 中国肿瘤临床
Chinese Journal of Clinical Oncology
; (24): 45-48, 2024.
Article
en Zh
| WPRIM
| ID: wpr-1026752
Biblioteca responsable:
WPRO
ABSTRACT
Acute myeloid leukemia(AML)is a heterogeneous myeloid malignancy.Currently,chemotherapy combined with hematopoietic stem cell transplantation is the primary treatment option;however,over-all prognosis remains poor.Gemtuzumab ozogamicin(GO)is a hu-manized CD33 monoclonal antibody conjugated with calicheamicins.It is primarily used to treat CD33-positive AML.Although studies have found that GO can improve the prognosis of patients with CD33-positive AML,some patients with AML do not benefit from it.Recent stud-ies have found that the effect of GO on AML is primarily associated with the expression of CD33 and its single nucleotide polymorphism(SNP),ATP-binding cassette subfamily B member 1(ABCB1)gene and SNP,as well as specific molecular biology and cytogenetics.This paper reviews the research progress on the factors influencing efficacy of GO for treating AML.
Texto completo:
1
Base de datos:
WPRIM
Idioma:
Zh
Revista:
Chinese Journal of Clinical Oncology
Año:
2024
Tipo del documento:
Article